Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Advanced Biliary Cancer
Interventions
DRUG

Gemox, Cetuximab

"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"

Trial Locations (1)

94800

Institut Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Merck Serono International SA

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT00552149 - Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin | Biotech Hunter | Biotech Hunter